Advanced Recurrent Ovarian Cancer- Pipeline Insight, 2024

Advanced Recurrent Ovarian Cancer- Pipeline Insight, 2024

DelveInsight’s, “Advanced Recurrent Ovarian Cancer- Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Advanced Recurrent Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Advanced Recurrent Ovarian Cancer Understanding

Advanced Recurrent Ovarian Cancer: Overview

Ovarian cancer refers to cancer that arises in the almond-shaped reproductive organs in women in which eggs, or ova, are produced (ovaries), in either of the two tubes through which eggs travel from the ovaries to the uterus (fallopian tubes), or in the membrane that lines the pelvis and the abdominal cavity and covers all of the abdominal organs (peritoneum). There are usually no symptoms (asymptomatic) during the early stages. As a result, ovarian cancer is usually not diagnosed until an advanced stage. Common symptoms that can develop include abdominal swelling or bloating, unintended weight loss, or changes in the bowel habits including constipation. The cause of ovarian cancer is multifactorial, which means that multiple factors that occur together are necessary for the cancer to develop. These factors include genetic, immunologic and environmental factors. About 20% of all women with ovarian cancer have a variation in one of two genes called BRCA1 or BRCA2. Ovarian cancer is a nonspecific term for a group of tumors. However, more than 90% of ovarian cancer arises from epithelial cells; these cells cover most internal and external surfaces of the body and its organs. Epithelial cancer of the ovaries, fallopian tubes, and peritoneum share similar behavior and characteristics. These closely related cancers are often grouped together and can be referred to as epithelial ovarian cancer or EOC. Affected individuals can develop abdominal bloating, the need to urinate quickly and frequently, changes in bowel habits including constipation, difficulty eating and a sense of feeling full quickly, unintended weight loss, and pelvic or abdominal pain or discomfort. Some women may have ascites, a condition characterized by the buildup of fluid in the abdomen. Additional symptoms that can develop including fatigue, back pain, an upset stomach, pain during sex, and changes to the menstrual cycle. Some women have an adnexal mass. An adnexal mass of the uterus is found in any area nearby the uterus that is related structurally or functionally. This includes the ovaries, fallopian tubes, and other nearby tissue. An adnexal mass can sometimes be the first sign of ovarian cancer and can cause a sense of pressure or pain in the pelvic region. The exact, underlying cause of ovarian cancer is not fully understood. The reason why cancer develops is a complex question and researchers speculate that multiple factors are involved in the development of ovarian cancer. These factors can include genetic, environmental and immunologic factors. Recurrent ovarian cancer is a lethal disease, and few patients can be cured. Although most patients receive standardized surgery and chemotherapy, the status of recurrent disease is heterogeneous. The site of recurrence and the survival intervals after recurrence are also widely distributed. The median interval to first recurrence is 18 to 24 months in ovarian cancer. Advanced ovarian cancer means that the cancer has spread outside the ovary. It may have spread within the pelvis or abdomen, or further away to other parts of the body such as the lungs. Some women have advanced ovarian cancer when they are first diagnosed, and treatment can cure their cancer. This depends on several factors, including the exact stage of the cancer. But for more advanced cancers, or those that come back after treatment, the aim of treatment is usually to: shrink the cancer, control it for as long as possible - this might be for many months and sometimes years, or control the symptoms.

""Advanced Recurrent Ovarian Cancer- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Recurrent Ovarian Cancer pipeline landscape is provided which includes the disease overview and Advanced Recurrent Ovarian Cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced Recurrent Ovarian Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Recurrent Ovarian Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Recurrent Ovarian Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Recurrent Ovarian Cancer.

Advanced Recurrent Ovarian Cancer Emerging Drugs Chapters

This segment of the Advanced Recurrent Ovarian Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Recurrent Ovarian Cancer Emerging Drugs

• Maveropepimut S: IMV

Maveropepimut-S (DPX-Survivac) combines the advantages of the DPX platform and the cancer antigen survivin, is the lead candidate of IMV’s new class of immunotherapies that generates cancer-targeted T cells in vivo. The protein survivin is found in more than 15 types of solid tumor and hematologic cancers. It has been recognized as a promising tumor-associated target because it is overexpressed in a high percentage of tumor types. It is believed Maveropepimut-S' ability to deliver a sustained flow of T cells that target survivin expressed on cancer cells can lead to more clinically effective anti-tumor therapies. Maveropepimut-S has demonstrated a robust and sustained, antigen-specific immune response with infiltration of targeted T cells into tumors post-treatment which is correlated with prolonged duration of clinical benefits up to more than two years. Maveropepimut-S showed a well-tolerated safety profile with no immune-related, serious systemic adverse events reported. Majority of adverse events being grade 1 and 2 injection site reactions. Compared to traditional immuno-oncology therapies, which require intravenous infusions and safety monitoring, Maveropepimut-S provides lesser burden on patients’ quality of life.

• ELU 001: Elucida Oncology

ELU001 is a novel, first-in-class, new molecular entity described as a C’Dot Drug Conjugate (CDC). ELU001 consists of ~12 folic acid targeting moieties and ~22 exatecan topoisomerase-1 inhibitor payloads on Cathepsin-B cleavable linkers covalently bound to the surface of each silicon core/polyethylene glycol C’Dot nanoparticle. CDCs are small in size, have a greater ability to penetrate into and through tumors as compared to ADCs, and are rapidly eliminated by the kidneys. The rapid systemic elimination is expected to lead to less toxicity than is observed with targeting platforms like ADCs that have a longer half-life in circulation. ELU001’s high avidity is believed to promote internalization into FRα overexpressing cancer cells, selectively delivering its payload. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.

• A166: Klus Pharma

A166 is a third-generation antibody-drug conjugate (ADC) that incorporates an anti-HER2 antibody conjugated to highly potent auristatin-based payload, via site-specific conjugation and cleavable Val-Cit linker. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.

Further product details are provided in the report……..

Advanced Recurrent Ovarian Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Recurrent Ovarian Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Advanced Recurrent Ovarian Cancer

There are approx. 10+ key companies which are developing the therapies for Advanced Recurrent Ovarian Cancer. The companies which have their Advanced Recurrent Ovarian Cancer drug candidates in the most advanced stage, i.e. phase II include, IMV.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Advanced Recurrent Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Recurrent Ovarian Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Recurrent Ovarian Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Recurrent Ovarian Cancer drugs.

Advanced Recurrent Ovarian Cancer Report Insights

• Advanced Recurrent Ovarian Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Advanced Recurrent Ovarian Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Advanced Recurrent Ovarian Cancer drugs?
• How many Advanced Recurrent Ovarian Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Recurrent Ovarian Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Recurrent Ovarian Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Advanced Recurrent Ovarian Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• IMV
• Elucida Oncology
• Klus Pharma
• Chia Tai Tianqing Pharmaceutical Group
• Sumitomo Pharma Oncology
• Precigen, Inc
• Glycotope GmbH

Key Products

• Maveropepimut S
• ELU 001
• A166
• TQ B3525
• TP-0903
• PRGN-3005 UltraCAR-T cells
• PankoMab-GEX